查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081955

基因治療市場：2026-2032年全球市場預測（按載體類型、治療類型、目標基因組、遞送方法、給藥途徑、患者類型、治療領域和最終用戶分類）

Gene Therapy Market by Vector Type, Therapy Type, Target Genome, Delivery Mode, Route of Administration, Patient Type, Therapeutic Area, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基因治療市場將成長至 759.2 億美元，複合年成長率為 28.80%。

主要市場統計數據
基準年 2025 129.1億美元
預計年份：2026年 163.5億美元
預測年份 2032 759.2億美元
複合年成長率 (%) 28.80%

基因療法正從高度專業化的研究領域發展成為針對罕見疾病、腫瘤、血液疾病、眼科疾病、神經系統疾病和遺傳代謝性疾病等疾病的臨床驗證治療模式。這一領域受益於不斷擴大的已批准的體內和體外療法，包括腺結合病毒（AAV）載體、慢病毒載體和基因組編輯技術。監管方面的里程碑事件，例如首批基於CRISPR技術的視網膜營養不良症、脊髓性肌肉萎縮症、多種CAR-T細胞療法以及鐮狀細胞病和輸血依賴型BETA-地中海貧血的獲批，都增強了人們對基因療法長期治療潛力的信心。

需求成長主要受以下因素驅動：未被滿足的龐大醫療需求、基因診斷率的提高、孤兒藥優先治療、新生兒篩檢的擴展以及更廣泛的臨床研發管線。然而，基因治療的商業化仍然面臨許多挑戰，因為基因治療需要專業的生產製造、低溫運輸物流、長期追蹤、基於價值的報銷機制以及嚴格的安全監測。能夠整合臨床證據、可擴展的生產能力、患者准入策略和監管合規性的機構，將有望引領基因治療產業邁入下一個發展階段。

基因治療前景的變革性變化

基因治療領域的格局正在轉變，從單一產品突破轉向基於平台的開發。申辦方擴大利用檢驗的載體、模組化生產流程和疾病特異性專業知識，以加速相關適應症的研發項目。這種轉變提高了臨床開發的效率，同時也提高了人們對永續性、安全性和可重複性的期望。

人工智慧對基因治療的累積影響

人工智慧 (AI) 透過改進標靶識別、載體設計、序列最佳化、患者分層和臨床試驗設計，正在基因治療價值鏈的各個環節創造累積價值。 AI 模型可以分析基因組、轉錄組、蛋白質組、影像、安全性以及真實世界數據，從而識別疾病機制並優先篩選出具有更強生物學證據的候選療法。

關鍵區域洞察：基因療法的區域應用

北美仍然是基因治療創新領域的領先地區，資金籌措、先進的大學附屬醫療中心、完善的罕見病支持網路、快速核准流程方面的監管經驗以及主導的契約研產機構（CDMO）基礎。美國在臨床試驗、法規核准和商業化方面引領區域活動，而加拿大則透過研究網路、細胞和基因治療生產舉措以及罕見疾病政策制定做出貢獻。

關鍵集團洞察：基因治療市場策略板塊

在新加坡、泰國和馬來西亞等市場，東協地區正崛起為基因治療領域的成長支柱，這主要得益於醫院基礎設施的改善、罕見疾病認知度的提高、基因檢測能力的增強以及醫療旅遊的蓬勃發展。然而，各地區的保險報銷體系成熟度、本地生產基礎設施的健全程度以及先進療法相關法規的協調性仍然存在差異，因此，區域間夥伴關係和「卓越中心」模式對於確保患者獲得治療至關重要。

重點國家洞察：優先基因治療市場

美國是基因療法商業性化程度最高的市場，這得益於其完善的監管體系、廣泛的臨床試驗、專業的治療中心、罕見疾病支持體係以及雄厚的生物技術資金籌措。加拿大正在加強其研發和生產能力，並透過省級醫保報銷計劃和國家罕見疾病舉措來改善治療的可及性。墨西哥和巴西是拉丁美洲的重要市場，其中巴西擁有該地區最強大的臨床研究和監管基礎。兩國都在持續努力降低治療成本、改善轉診途徑、普及基因檢測並發展專業的治療中心。

為基因治療產業領導者提供的實用建議

產業領導者應從研發早期階段就優先考慮可擴展的生產結構，包括載體製程最佳化、分析驗證、功效測量策略以及關鍵原料的雙源採購策略。完善的化學、生產和品管(CMC) 計劃至關重要，因為品質的可比性、批次間的一致性以及出貨檢驗的可靠性都會影響監管申報進度和商業化準備。

調查方法

本調查方法基於「三角測量」法，結合了監管資訊、臨床試驗分析、公開資訊、科學文獻、專利趨勢、報銷方案趨勢以及區域醫療基礎設施評估。優先資訊來源包括公共監管資料庫、同儕審查文章、衛生技術評估（HTA）文件、公共文件、治療指南、經認證的臨床試驗註冊庫以及政府醫療政策文件。

結論：基因治療的策略展望

在科學檢驗、監管機構認可和患者需求的推動下，基因療法正進入關鍵成長階段。未來引領該行業的企業，將是那些將突破性生物學研究與強大的生產能力、安全性、持續療效和可靠的醫保報銷機制相結合的公司。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 基因治療市場：依載體類型分類

  • 非病毒載體
    • 脂質體
    • 質體DNA
  • 病毒載體
    • 腺結合病毒（AAV）載體
    • 腺病毒載體
    • 單純皰疹病毒（HSV）載體
    • 逆轉錄病毒載體

第8章 基因治療市場：依治療類型分類

  • 基因替代療法
  • 基因靜默療法
  • 基因編輯療法
  • 基因增強療法
  • 基於細胞的基因治療

第9章 基因治療市場：以標靶基因組分類

  • DNA修飾
  • RNA修飾

第10章 基因治療市場：依給藥方式分類

  • Ex Vivo
  • 體內

第11章 基因治療市場：依給藥途徑分類

  • 肌肉內部
  • 眼
  • 靜脈

第12章 基因治療市場：依患者類型分類

  • 成年患者
  • 兒童患者

第13章 基因治療市場：依治療領域分類

  • 心血管疾病
    • 缺血性心臟疾病
    • 心臟衰竭
  • 感染疾病
    • B型肝炎
    • HIV
  • 單基因疾病
    • 囊腫纖維化
    • 血友病
    • 鐮狀細胞貧血症
  • 腫瘤性疾病
    • 骨髓惡性腫瘤
    • 固體癌

第14章 基因治療市場：依最終用戶分類

  • 受託研究機構
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第15章 基因治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章 基因治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 基因治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abeona Therapeutics Inc.
  • Adaptimmune Therapeutics PLC
  • Adverum Biotechnologies, Inc.
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis SA
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intellia Therapeutics
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Syncona Limited
  • ViGeneron GmbH
  • Voyager Therapeutics Inc.
Product Code: MRR-437517DB6C62

The Gene Therapy Market is projected to grow by USD 75.92 billion at a CAGR of 28.80% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.91 billion
Estimated Year [2026] USD 16.35 billion
Forecast Year [2032] USD 75.92 billion
CAGR (%) 28.80%

Gene therapy is moving from a highly specialized research field into a clinically validated treatment model for rare diseases, oncology, hematology, ophthalmology, neurology, and inherited metabolic disorders. The field is supported by a growing base of approved in vivo and ex vivo therapies, including adeno-associated virus (AAV) vectors, lentiviral vectors, and genome-editing approaches. Regulatory milestones, including approvals of retinal dystrophy therapy, spinal muscular atrophy therapy, multiple CAR-T cell therapies, and the first CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia, have strengthened confidence in long-term therapeutic potential.

Demand is being shaped by high unmet medical need, increasing genetic diagnosis rates, orphan drug incentives, newborn screening expansion, and broader clinical pipelines. At the same time, commercialization remains complex because gene therapy requires specialized manufacturing, cold-chain logistics, long-term follow-up, value-based reimbursement, and rigorous safety monitoring. Organizations that can integrate clinical evidence, scalable production, patient access strategy, and regulatory alignment are positioned to lead the next phase of the gene therapy industry.

Transformative Shifts in the Gene Therapy Landscape

The gene therapy landscape is being transformed by the transition from single-product breakthroughs to platform-based development. Sponsors are increasingly using validated vectors, modular manufacturing processes, and disease-area expertise to accelerate programs across related indications. This shift is improving clinical development efficiency while raising expectations for durability, safety, and reproducibility.

Manufacturing capacity has become a strategic differentiator. Viral vector supply constraints, quality control requirements, potency assay complexity, and high cost of goods continue to influence launch timelines and access strategies. In parallel, non-viral delivery, lipid nanoparticles, base editing, prime editing, targeted in vivo delivery, and improved capsid engineering are expanding the competitive field beyond traditional viral vector platforms.

The commercial model is also changing. Payers are demanding evidence of long-term clinical benefit, especially for one-time therapies with high upfront treatment costs. As a result, outcomes-based agreements, installment payment models, registries, and real-world evidence programs are becoming central to gene therapy market access strategy.

Cumulative Impact of Artificial Intelligence in Gene Therapy

Artificial intelligence is creating cumulative value across the gene therapy value chain by improving target identification, vector engineering, sequence optimization, patient stratification, and clinical trial design. AI-enabled models can analyze genomic, transcriptomic, proteomic, imaging, safety, and real-world datasets to identify disease mechanisms and prioritize therapeutic candidates with stronger biological rationale.

In development and manufacturing, AI supports process monitoring, predictive quality analytics, assay optimization, deviation detection, and batch-failure reduction. These capabilities are particularly relevant for viral vector production, where yield variability, impurity profiles, and release testing can affect both cost and supply reliability. AI is also being applied to adverse-event signal detection and long-term follow-up analytics, supporting regulatory compliance for therapies that may require monitoring for years after administration.

The impact is cumulative rather than isolated: each dataset generated during discovery, clinical trials, manufacturing, and post-market surveillance improves future decision-making. Organizations with governed data infrastructure, validated models, privacy-compliant data use, and cross-functional AI adoption are likely to shorten development cycles and strengthen evidence generation.

Key Regional Insights: Gene Therapy Adoption by Region

North America remains the leading region for gene therapy innovation, supported by deep biotechnology financing, advanced academic medical centers, established rare disease advocacy networks, regulatory experience with expedited pathways, and a strong base of contract development and manufacturing organizations. The United States anchors regional activity through clinical trials, regulatory approvals, and commercial launches, while Canada contributes through research networks, cell and gene therapy manufacturing initiatives, and rare disease policy development.

Europe is a major hub for advanced therapy medicinal products, with a dedicated ATMP regulatory framework and strong clinical infrastructure across Germany, France, Italy, Spain, and the United Kingdom. Country-specific health technology assessment processes and pricing negotiations can slow patient access after approval, but the region's emphasis on real-world evidence, managed entry agreements, and cross-border scientific collaboration is shaping global reimbursement standards for advanced therapies.

Asia-Pacific is expanding rapidly as China, Japan, South Korea, Australia, India, and ASEAN markets invest in biotechnology infrastructure, clinical trial capacity, genomic medicine, and domestic manufacturing. China has become a major center for cell therapy trials and gene-editing research, while Japan's regenerative medicine framework supports accelerated development pathways and South Korea continues to strengthen biomanufacturing capabilities. Latin America, led by Brazil and Mexico, is building access through specialized centers and regulatory modernization, although affordability, diagnostic coverage, and infrastructure gaps remain important barriers. The Middle East, particularly GCC countries, is investing in precision medicine, genomic screening, and tertiary care, while Africa's opportunity is tied to genomics capacity, diagnostic access, newborn screening, and partnerships addressing high-burden inherited conditions such as hemoglobinopathies.

Key Group Insights: Strategic Gene Therapy Market Blocs

ASEAN is emerging as a growth corridor for gene therapy through improving hospital infrastructure, rising rare disease awareness, increased genetic testing capacity, and medical tourism in markets such as Singapore, Thailand, and Malaysia. However, reimbursement maturity, local manufacturing depth, and advanced therapy regulatory harmonization remain uneven, making regional partnerships and centers-of-excellence models critical for access.

The GCC is prioritizing precision medicine, genomic screening, and high-acuity specialty care, particularly in Saudi Arabia, the United Arab Emirates, and Qatar. These markets are well positioned to adopt advanced therapies through centralized health systems, national transformation programs, and investment in specialty hospitals, but long-term follow-up systems, outcomes tracking, and cost-management frameworks are essential for sustainable uptake.

The European Union provides one of the most structured regulatory environments through the ATMP framework, while joint clinical assessment under evolving EU health technology assessment rules is expected to influence evidence expectations and access planning. BRICS countries represent a large long-term opportunity due to population scale, genetic disease burden, expanding clinical research, and increasing domestic biotech investment, though access varies widely by healthcare financing model and specialist infrastructure. G7 countries continue to dominate approvals, clinical development, manufacturing quality systems, and reimbursement innovation, while NATO member markets overlap significantly with advanced healthcare systems investing in supply-chain resilience, biosecurity, health security, and domestic advanced therapy manufacturing.

Key Country Insights: Priority Gene Therapy Markets

The United States is the most commercially advanced gene therapy market, with strong regulatory precedent, broad clinical trial activity, specialized treatment centers, rare disease advocacy, and significant biotechnology financing. Canada is strengthening research and manufacturing capacity while addressing access through provincial reimbursement pathways and national rare disease policy initiatives. Mexico and Brazil are important Latin American markets, with Brazil offering the region's strongest clinical research and regulatory base, while both countries continue to address affordability, referral pathways, genetic testing availability, and specialized treatment-center capacity.

In Europe, the United Kingdom combines scientific leadership with an innovative medicines environment and strong genomic medicine infrastructure, while Germany and France are central to clinical adoption, pricing negotiations, hospital-based delivery, and health technology assessment influence. Italy and Spain have strong specialist networks and experience with managed access for advanced therapies. Russia has scientific capabilities in biomedical research, but geopolitical, regulatory, and supply-chain factors influence international collaboration and access to advanced therapy inputs.

China is one of the most active gene therapy and cell therapy development markets, supported by large patient populations, domestic biotechnology investment, expanding regulatory maturity, and growing hospital-based clinical trial capacity. India offers long-term potential through genetic disease burden, cost-efficient manufacturing, improving genomic diagnostics, and a growing biotech sector. Japan provides a favorable environment for regenerative medicine and advanced therapies, South Korea is investing heavily in biomanufacturing and translational research, and Australia contributes through clinical trial excellence, hospital networks, rare disease programs, and government-supported medical research.

Actionable Recommendations for Gene Therapy Industry Leaders

Industry leaders should prioritize scalable manufacturing early in development, including vector process optimization, analytical validation, potency assay strategy, and dual-sourcing strategies for critical raw materials. Robust chemistry, manufacturing, and controls planning is essential because quality comparability, batch consistency, and release testing reliability can determine regulatory timelines and commercial readiness.

Market access should be built into the clinical strategy rather than added after approval. Sponsors need endpoints that demonstrate durable patient benefit, registries that support long-term evidence generation, and payer engagement models that address high upfront therapy costs. Outcomes-based reimbursement, staged payments, annuity-style models, and risk-sharing agreements should be evaluated where legally and operationally feasible.

Organizations should also invest in AI-enabled data infrastructure, decentralized patient identification, genetic testing partnerships, newborn screening alignment, and centers-of-excellence networks. These capabilities improve trial recruitment, shorten diagnostic delays, and support safe administration in real-world settings. Strategic alliances with academic institutions, manufacturing partners, diagnostic providers, patient organizations, and regional health systems can accelerate responsible global expansion.

Research Methodology

The research methodology is developed using a triangulated research approach that combines regulatory intelligence, clinical trial analysis, public disclosures, scientific literature, patent trends, reimbursement developments, and regional healthcare infrastructure assessment. Priority sources include public regulatory databases, peer-reviewed publications, health technology assessment documents, public filings, treatment guidelines, recognized clinical trial registries, and government healthcare policy documents.

The methodology emphasizes verified and current evidence rather than speculative market claims. Insights are cross-checked across multiple source categories to evaluate approval momentum, pipeline direction, technology adoption, manufacturing constraints, patient access dynamics, and safety monitoring requirements. Regional, group, and country assessments consider regulatory maturity, financing capacity, treatment-center infrastructure, genetic testing availability, long-term follow-up systems, and policy support for advanced therapies.

Conclusion: Strategic Outlook for Gene Therapy

Gene therapy is entering a decisive growth phase as scientific validation, regulatory experience, and patient demand converge. The industry's next leaders will be those that combine breakthrough biology with manufacturability, safety, durable outcomes, and credible reimbursement evidence.

Artificial intelligence, next-generation delivery systems, genomic diagnostics, and global manufacturing investment are expected to reshape development productivity and access. However, the sector must continue to address affordability, long-term monitoring, equitable patient identification, and scalable delivery through qualified treatment centers. For industry leaders, the strategic priority is clear: build integrated platforms that connect discovery, manufacturing, clinical evidence, safety surveillance, and market access from the earliest stages of development.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gene Therapy Market, by Vector Type

  • 7.1. Non-Viral Vectors
    • 7.1.1. Lipofection
    • 7.1.2. Plasmid DNA
  • 7.2. Viral Vectors
    • 7.2.1. Adeno-Associated Virus (AAV) Vectors
    • 7.2.2. Adenovirus Vectors
    • 7.2.3. Herpes Simplex Virus (HSV) Vectors
    • 7.2.4. Retrovirus Vectors

8. Gene Therapy Market, by Therapy Type

  • 8.1. Gene Replacement Therapy
  • 8.2. Gene Silencing Therapy
  • 8.3. Gene Editing Therapy
  • 8.4. Gene Augmentation Therapy
  • 8.5. Cell-Based Gene Therapy

9. Gene Therapy Market, by Target Genome

  • 9.1. DNA Modification
  • 9.2. RNA Modification

10. Gene Therapy Market, by Delivery Mode

  • 10.1. Ex Vivo
  • 10.2. In Vivo

11. Gene Therapy Market, by Route of Administration

  • 11.1. Intramuscular
  • 11.2. Intraocular
  • 11.3. Intravenous

12. Gene Therapy Market, by Patient Type

  • 12.1. Adult Patients
  • 12.2. Pediatric Patients

13. Gene Therapy Market, by Therapeutic Area

  • 13.1. Cardiovascular Diseases
    • 13.1.1. Coronary Artery Disease
    • 13.1.2. Heart Failure
  • 13.2. Infectious Diseases
    • 13.2.1. Hepatitis B
    • 13.2.2. HIV
  • 13.3. Monogenic Disorders
    • 13.3.1. Cystic Fibrosis
    • 13.3.2. Hemophilia
    • 13.3.3. Sickle Cell Anemia
  • 13.4. Oncological Disorders
    • 13.4.1. Hematological Malignancies
    • 13.4.2. Solid Tumors

14. Gene Therapy Market, by End-User

  • 14.1. Contract Research Organizations
  • 14.2. Hospitals & Clinics
  • 14.3. Pharmaceutical & Biotech Companies
  • 14.4. Research Institutes

15. Gene Therapy Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Gene Therapy Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Gene Therapy Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abeona Therapeutics Inc.
  • 19.2. Adaptimmune Therapeutics PLC
  • 19.3. Adverum Biotechnologies, Inc.
  • 19.4. AGC Biologics
  • 19.5. Alnylam Pharmaceuticals, Inc.
  • 19.6. American Gene Technologies Inc.
  • 19.7. Amgen Inc.
  • 19.8. AnGes, Inc.
  • 19.9. Astellas Pharma Inc.
  • 19.10. Biogen Inc.
  • 19.11. bluebird bio, Inc.
  • 19.12. Cellectis S.A.
  • 19.13. CRISPR Therapeutics AG
  • 19.14. Danaher Corporation
  • 19.15. Editas Medicine, Inc.
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. Gilead Sciences, Inc.
  • 19.18. Intellia Therapeutics
  • 19.19. Ionis Pharmaceuticals, Inc.
  • 19.20. Johnson & Johnson
  • 19.21. Merck KGaA
  • 19.22. Mustang Bio, Inc.
  • 19.23. Novartis AG
  • 19.24. Orchard Therapeutics PLC
  • 19.25. Poseida Therapeutics, Inc.
  • 19.26. Sangamo Therapeutics, Inc.
  • 19.27. Sarepta Therapeutics, Inc.
  • 19.28. Sibiono GeneTech Co. Ltd.
  • 19.29. Syncona Limited
  • 19.30. ViGeneron GmbH
  • 19.31. Voyager Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENE THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL GENE THERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL GENE THERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL GENE THERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIPOFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIPOFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIPOFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PLASMID DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PLASMID DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PLASMID DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VIRAL VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VIRAL VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VIRAL VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ADENO-ASSOCIATED VIRUS (AAV) VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ADENOVIRUS VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADENOVIRUS VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADENOVIRUS VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HERPES SIMPLEX VIRUS (HSV) VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RETROVIRUS VECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENE REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENE REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENE SILENCING THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENE SILENCING THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENE SILENCING THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENE EDITING THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENE AUGMENTATION THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENE AUGMENTATION THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENE AUGMENTATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CELL-BASED GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL-BASED GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CELL-BASED GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DNA MODIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA MODIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA MODIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA MODIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA MODIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA MODIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INTRAOCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INTRAOCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INTRAOCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIOVASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HEART FAILURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HEART FAILURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HEART FAILURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MONOGENIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HEMOPHILIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HEMOPHILIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HEMOPHILIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL SICKLE CELL ANEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLOGICAL DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL PHARMACEUTICAL & BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. GCC GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. GCC GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 237. GCC GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 240. GCC GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 241. GCC GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. GCC GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 244. GCC GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. GCC GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 248. GCC GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 279. G7 GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. G7 GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. G7 GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 285. G7 GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 287. G7 GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. G7 GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 289. G7 GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 290. G7 GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 291. G7 GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 292. G7 GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 293. G7 GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 294. NATO GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 295. NATO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. NATO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 300. NATO GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 301. NATO GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. NATO GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. NATO GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 304. NATO GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 305. NATO GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 306. NATO GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 307. NATO GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 308. NATO GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 309. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED STATES GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED STATES GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED STATES GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED STATES GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 325. CANADA GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. CANADA GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. CANADA GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 328. CANADA GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 329. CANADA GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. CANADA GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 331. CANADA GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 332. CANADA GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 333. CANADA GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. CANADA GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 335. CANADA GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 336. CANADA GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 337. CANADA GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 338. CANADA GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 339. CANADA GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 340. MEXICO GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 341. MEXICO GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 342. MEXICO GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 343. MEXICO GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 344. MEXICO GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. MEXICO GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 346. MEXICO GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 347. MEXICO GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 348. MEXICO GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. MEXICO GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 350. MEXICO GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 351. MEXICO GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 352. MEXICO GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 353. MEXICO GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 354. MEXICO GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 355. BRAZIL GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 356. BRAZIL GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. BRAZIL GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 358. BRAZIL GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 359. BRAZIL GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 360. BRAZIL GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD MILLION)
  • TABLE 361. BRAZIL GENE THERAPY MARKET SIZE, BY DELIVERY MODE, 2018-2032 (USD MILLION)
  • TABLE 362. BRAZIL GENE THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 363. BRAZIL GENE THERAPY MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 364. BRAZIL GENE THERAPY MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 365. BRAZIL GENE THERAPY MARKET SIZE, BY CARDIOVASCULAR DISEASES, 2018-2032 (USD MILLION)
  • TABLE 366. BRAZIL GENE THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 367. BRAZIL GENE THERAPY MARKET SIZE, BY MONOGENIC DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 368. BRAZIL GENE THERAPY MARKET SIZE, BY ONCOLOGICAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 369. BRAZIL GENE THERAPY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 370. UNITED KINGDOM GENE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 371. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 372. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY NON-VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 373. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY VIRAL VECTORS, 2018-2032 (USD MILLION)
  • TABLE 374. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 375. UNITED KINGDOM GENE THERAPY MARKET SIZE, BY TARGET GENOME, 2018-2032 (USD M